GOLDMAN SACHS GROUP INC - ENLIVEX THERAPEUTICS LTD ownership

ENLIVEX THERAPEUTICS LTD's ticker is ENLV and the CUSIP is M4130Y106. A total of 22 filers reported holding ENLIVEX THERAPEUTICS LTD in Q2 2021. The put-call ratio across all filers is 10.97 and the average weighting 0.0%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of ENLIVEX THERAPEUTICS LTD
ValueSharesWeighting
Q2 2023$29,681
-56.8%
11,297
-40.1%
0.00%
Q1 2023$68,687
-7.7%
18,870
-0.2%
0.00%
Q4 2022$74,450
-15.4%
18,908
-8.8%
0.00%
Q3 2022$88,000
+29.4%
20,729
+69.8%
0.00%
Q1 2022$68,000
-52.8%
12,205
-6.0%
0.00%
Q1 2021$144,00012,9860.00%
Other shareholders
ENLIVEX THERAPEUTICS LTD shareholders Q2 2021
NameSharesValueWeighting ↓
ACT CAPITAL MANAGEMENT, LLC 15,000$68,0000.10%
Susquehanna International Group Ltd. 22,002$98,0000.02%
ARK Investment Management 331,001$1,658,0000.01%
Compagnie Lombard Odier SCmA 50,000$223,0000.01%
EDMOND DE ROTHSCHILD HOLDING S.A. 13,000$59,0000.00%
OSAIC HOLDINGS, INC. 400$2,0000.00%
BANK OF AMERICA CORP /DE/ 1,215$5,0000.00%
WELLS FARGO & COMPANY/MN 12,373$56,0000.00%
CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0$00.00%
GROUP ONE TRADING, L.P. 2,884$13,0000.00%
View complete list of ENLIVEX THERAPEUTICS LTD shareholders